Pharma News, 2022

NMD Pharma has received FDA’s Orphan Drug designation for its NMD670 candidate for treatment of myasthenia gravis.

Long ignored, dipole-dipole interactions give life its shape.

The European Medicines Agency (EMA) reported that Boehringer Ingelheim’s Actilyse (alteplase), Actilyse Cathlo (alteplase) and Metalyse (tenecteplase) are in short supply. ...

Pfizer and BioNTech have completed an Emergency Use Authorization (EUA) submission for their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for children between the ages of five and 11. ...

AstraZeneca and Merck have withdrawn Lynparza (olaparib) for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated ovarian cancer who have been treated wit...

The UK’s National Institute for Health and Care Excellence (NICE) has recommended Pfizer’s Ibrance (palbociclib) plus fulvestrant for National Health Service (NHS) use as a treatment for  ...

The FDA has granted Fast Track Designation for Atea Pharmaceuticals Inc's  AT-752 for treating dengue virus infection.

A Boston biotech focused on liver disease raised some quick cash last week, selling royalty rights to its sole FDA-approved drug.

The FDA has granted an Orphan Drug designation to Sweden-based Infant Bacterial Therapeutics’ investigational drug arginyl-glutamine dipeptide to prevent retinopathy of prematurity (ROP), a cond...

In an FDA advisory committee meeting on Thursday afternoon, few punches were pulled as oncology experts assessed Oncopeptides’ multiple myeloma treatment Pepaxto (melflufen). ...

Two years after blessing Eli Lilly’s Retevmo to treat lung and thyroid cancers caused by a specific biomarker, the FDA has authorized the drug to be used across all tumor types that bear the bio...

Pfizer has promised to supply up to six million treatment courses of its Paxlovid (nirmatrelvir, ritonavir) to the Global Fund for treatment of COVID-19 infections. ...